Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1992 Jan 1;89(1):128–131. doi: 10.1073/pnas.89.1.128

Cellular oxidative modification of low density lipoprotein does not require lipoxygenases.

C P Sparrow 1, J Olszewski 1
PMCID: PMC48189  PMID: 1729678

Abstract

The oxidative modification of low density lipoprotein (LDL) may play an important role in the pathogenesis of atherosclerosis. LDL can be oxidatively modified in vitro by endothelial cells, mouse peritoneal macrophages, or copper ions. Studies using lipoxygenase inhibitors have suggested that lipoxygenase(s) is required for the cellular modification of LDL [Rankin, S. M., Parthasarathy, S. & Steinberg, D. (1991) J. Lipid Res. 32, 449-456]. We have reexamined the effect of lipoxygenase inhibitors on cellular modification and found that (i) inhibitors specific for 5-lipoxygenase do not block LDL modification; (ii) inhibitors that block lipoxygenase by donating one electron to the enzyme (reductive inactivation) prevent LDL modification by cells and also modification mediated by copper ions, implying that they act as general antioxidants; (iii) the lipoxygenase inhibitor 5,8,11,14-eicosatetraynoic acid blocks 15-lipoxygenase activity in intact macrophages at concentrations 100 times less than those required to block LDL modification by macrophages; and (iv) 5,8,11,14-eicosatetraynoic acid is cytotoxic at concentrations about twice those required to prevent modification. Furthermore, macrophages and the RECB4 line of endothelial cells modify LDL with similar efficiencies despite dramatic differences in 15-lipoxygenase activity. Thus we conclude that neither 5-lipoxygenase nor 15-lipoxygenase is required for modification of LDL by cultured cells.

Full text

PDF
128

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLIGH E. G., DYER W. J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 Aug;37(8):911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  2. Bird, Bruneau P., Crawley G. C., Edwards M. P., Foster S. J., Girodeau J. M., Kingston J. F., McMillan R. M. (Methoxyalkyl)thiazoles: a new series of potent, selective, and orally active 5-lipoxygenase inhibitors displaying high enantioselectivity. J Med Chem. 1991 Jul;34(7):2176–2186. doi: 10.1021/jm00111a038. [DOI] [PubMed] [Google Scholar]
  3. Bonney R. J., Davies P., Dougherty H., Egan R. W., Gale P. H., Chang M., Hammond M., Jensen N., MacDonald J., Thompson K. Biochemical and biological activities of 2,3-dihydro-6-[3-(2-hydroxymethyl)phenyl-2-propenyl]-5-benzofuranol (L-651,896), a novel topical anti-inflammatory agent. Biochem Pharmacol. 1987 Nov 15;36(22):3885–3891. doi: 10.1016/0006-2952(87)90454-0. [DOI] [PubMed] [Google Scholar]
  4. Bryant R. W., Bailey J. M., Schewe T., Rapoport S. M. Positional specificity of a reticulocyte lipoxygenase. Conversion of arachidonic acid to 15-S-hydroperoxy-eicosatetraenoic acid. J Biol Chem. 1982 Jun 10;257(11):6050–6055. [PubMed] [Google Scholar]
  5. Buchanan M. R., Haas T. A., Lagarde M., Guichardant M. 13-Hydroxyoctadecadienoic acid is the vessel wall chemorepellant factor, LOX. J Biol Chem. 1985 Dec 25;260(30):16056–16059. [PubMed] [Google Scholar]
  6. Buonassisi V., Venter J. C. Hormone and neurotransmitter receptors in an established vascular endothelial cell line. Proc Natl Acad Sci U S A. 1976 May;73(5):1612–1616. doi: 10.1073/pnas.73.5.1612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carter G. W., Young P. R., Albert D. H., Bouska J., Dyer R., Bell R. L., Summers J. B., Brooks D. W. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther. 1991 Mar;256(3):929–937. [PubMed] [Google Scholar]
  8. Cathcart M. K., McNally A. K., Morel D. W., Chisolm G. M., 3rd Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. J Immunol. 1989 Mar 15;142(6):1963–1969. [PubMed] [Google Scholar]
  9. Dixon R. A., Diehl R. E., Opas E., Rands E., Vickers P. J., Evans J. F., Gillard J. W., Miller D. K. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 1990 Jan 18;343(6255):282–284. doi: 10.1038/343282a0. [DOI] [PubMed] [Google Scholar]
  10. Downing D. T., Ahern D. G., Bachta M. Enzyme inhibition by acetylenic compounds. Biochem Biophys Res Commun. 1970 Jul 13;40(1):218–223. doi: 10.1016/0006-291x(70)91069-7. [DOI] [PubMed] [Google Scholar]
  11. Gillard J., Ford-Hutchinson A. W., Chan C., Charleson S., Denis D., Foster A., Fortin R., Leger S., McFarlane C. S., Morton H. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol. 1989 May;67(5):456–464. doi: 10.1139/y89-073. [DOI] [PubMed] [Google Scholar]
  12. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hiramatsu K., Rosen H., Heinecke J. W., Wolfbauer G., Chait A. Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arteriosclerosis. 1987 Jan-Feb;7(1):55–60. doi: 10.1161/01.atv.7.1.55. [DOI] [PubMed] [Google Scholar]
  14. Ibe B. O., Falck J. R., Johnson A. R., Campbell W. B. Regulation of synthesis of prostacyclin and HETEs in human endothelial cells. Am J Physiol. 1989 Jun;256(6 Pt 1):C1168–C1175. doi: 10.1152/ajpcell.1989.256.6.C1168. [DOI] [PubMed] [Google Scholar]
  15. Kemal C., Louis-Flamberg P., Krupinski-Olsen R., Shorter A. L. Reductive inactivation of soybean lipoxygenase 1 by catechols: a possible mechanism for regulation of lipoxygenase activity. Biochemistry. 1987 Nov 3;26(22):7064–7072. doi: 10.1021/bi00396a031. [DOI] [PubMed] [Google Scholar]
  16. Kühn H., Sprecher H., Brash A. R. On singular or dual positional specificity of lipoxygenases. The number of chiral products varies with alignment of methylene groups at the active site of the enzyme. J Biol Chem. 1990 Sep 25;265(27):16300–16305. [PubMed] [Google Scholar]
  17. Mathur S. N., Albright E., Field F. J. Regulation of 12-hydroxyeicosatetraenoic acid synthesis by acetyl-LDL in mouse peritoneal macrophages. Biochim Biophys Acta. 1989 Jan 23;1001(1):50–59. doi: 10.1016/0005-2760(89)90306-8. [DOI] [PubMed] [Google Scholar]
  18. Palinski W., Rosenfeld M. E., Ylä-Herttuala S., Gurtner G. C., Socher S. S., Butler S. W., Parthasarathy S., Carew T. E., Steinberg D., Witztum J. L. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989 Feb;86(4):1372–1376. doi: 10.1073/pnas.86.4.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Parthasarathy S., Wieland E., Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci U S A. 1989 Feb;86(3):1046–1050. doi: 10.1073/pnas.86.3.1046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pittman R. C., Taylor C. A., Jr Methods for assessment of tissue sites of lipoprotein degradation. Methods Enzymol. 1986;129:612–628. doi: 10.1016/0076-6879(86)29094-1. [DOI] [PubMed] [Google Scholar]
  21. Rankin S. M., Parthasarathy S., Steinberg D. Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J Lipid Res. 1991 Mar;32(3):449–456. [PubMed] [Google Scholar]
  22. Riendeau D., Falgueyret J. P., Guay J., Ueda N., Yamamoto S. Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction. Biochem J. 1991 Feb 15;274(Pt 1):287–292. doi: 10.1042/bj2740287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Riendeau D., Falgueyret J. P., Nathaniel D. J., Rokach J., Ueda N., Yamamoto S. Sensitivity of immunoaffinity-purified porcine 5-lipoxygenase to inhibitors and activating lipid hydroperoxides. Biochem Pharmacol. 1989 Jul 15;38(14):2313–2321. doi: 10.1016/0006-2952(89)90471-1. [DOI] [PubMed] [Google Scholar]
  24. Salari H., Braquet P., Borgeat P. Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. Prostaglandins Leukot Med. 1984 Jan;13(1):53–60. doi: 10.1016/0262-1746(84)90102-1. [DOI] [PubMed] [Google Scholar]
  25. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983 May 6;220(4597):568–575. doi: 10.1126/science.6301011. [DOI] [PubMed] [Google Scholar]
  26. Sigal E., Grunberger D., Highland E., Gross C., Dixon R. A., Craik C. S. Expression of cloned human reticulocyte 15-lipoxygenase and immunological evidence that 15-lipoxygenases of different cell types are related. J Biol Chem. 1990 Mar 25;265(9):5113–5120. [PubMed] [Google Scholar]
  27. Simon T. C., Makheja A. N., Bailey J. M. Formation of 15-hydroxyeicosatetraenoic acid (15-HETE) as the predominant eicosanoid in aortas from Watanabe Heritable Hyperlipidemic and cholesterol-fed rabbits. Atherosclerosis. 1989 Jan;75(1):31–38. doi: 10.1016/0021-9150(89)90204-9. [DOI] [PubMed] [Google Scholar]
  28. Soberman R. J. 5- and 15(omega-6)-lipoxygenases from human polymorphonuclear leukocytes. Methods Enzymol. 1988;163:344–349. doi: 10.1016/0076-6879(88)63033-3. [DOI] [PubMed] [Google Scholar]
  29. Sparrow C. P., Parthasarathy S., Steinberg D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem. 1989 Feb 15;264(5):2599–2604. [PubMed] [Google Scholar]
  30. Sparrow C. P., Parthasarathy S., Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. J Lipid Res. 1988 Jun;29(6):745–753. [PubMed] [Google Scholar]
  31. Spector A. A., Gordon J. A., Moore S. A. Hydroxyeicosatetraenoic acids (HETEs). Prog Lipid Res. 1988;27(4):271–323. doi: 10.1016/0163-7827(88)90009-4. [DOI] [PubMed] [Google Scholar]
  32. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 Apr 6;320(14):915–924. doi: 10.1056/NEJM198904063201407. [DOI] [PubMed] [Google Scholar]
  33. Steinbrecher U. P., Parthasarathy S., Leake D. S., Witztum J. L., Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3883–3887. doi: 10.1073/pnas.81.12.3883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sun F. F., McGuire J. C. Inhibition of human neutrophil arachidonate 5-lipoxygenase by 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1 (U-60257). Prostaglandins. 1983 Aug;26(2):211–221. doi: 10.1016/0090-6980(83)90090-4. [DOI] [PubMed] [Google Scholar]
  35. Wilkins G. M., Leake D. S. Free radicals and low-density lipoprotein oxidation by macrophages. Biochem Soc Trans. 1990 Dec;18(6):1170–1171. doi: 10.1042/bst0181170. [DOI] [PubMed] [Google Scholar]
  36. Yamamoto S. "Enzymatic" lipid peroxidation: reactions of mammalian lipoxygenases. Free Radic Biol Med. 1991;10(2):149–159. doi: 10.1016/0891-5849(91)90008-q. [DOI] [PubMed] [Google Scholar]
  37. Ylä-Herttuala S., Palinski W., Rosenfeld M. E., Parthasarathy S., Carew T. E., Butler S., Witztum J. L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989 Oct;84(4):1086–1095. doi: 10.1172/JCI114271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ylä-Herttuala S., Rosenfeld M. E., Parthasarathy S., Glass C. K., Sigal E., Witztum J. L., Steinberg D. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6959–6963. doi: 10.1073/pnas.87.18.6959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ylä-Herttuala S., Rosenfeld M. E., Parthasarathy S., Sigal E., Särkioja T., Witztum J. L., Steinberg D. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest. 1991 Apr;87(4):1146–1152. doi: 10.1172/JCI115111. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES